Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting

Rhea-AI Summary

Tempest Therapeutics (Nasdaq: TPST) announced the acceptance of an abstract for the 2023 ASCO Annual Meeting, scheduled for June 2-6, 2023, in Chicago. The abstract focuses on TPST-1495, an EP2/EP4 prostaglandin receptor dual antagonist.

Presentation Details:

• Title: A Phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors
• Session Title: Developmental Therapeutics — Molecularly Targeted Agents and Tumor Biology
• Session Date and Time: June 3, 2023; 8:00 a.m. – 11:00 a.m. ET
• Abstract Number: 3107

The abstract will be released on May 25, 2023, at 5:00 p.m. ET on the ASCO website.

Positive

• Acceptance of TPST-1495 abstract for presentation at ASCO, indicating ongoing research interest.
• Potential of TPST-1495 to treat advanced solid tumors in combination with pembrolizumab, showcasing innovative therapy.

Negative

• None.

BRISBANE, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class¹ therapeutics that combine both targeted and immune-mediated mechanisms, today announced the acceptance of an abstract on TPST-1495, a EP2/EP4 prostaglandin receptor dual antagonist, for a poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 at the McCormick Place Convention Center in Chicago, IL.

Presentation details:

Title: A Phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors
Session Title: Developmental Therapeutics — Molecularly Targeted Agents and Tumor Biology
Session Date and Time: Saturday, June 3, 2023; 8:00 a.m. – 11:00 a.m. ET
Abstract Number: 3107

The abstract will be released on Thursday, May 25, 2023 at 5:00 p.m. ET on meetings.asco.org.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company has a diverse portfolio of novel programs ranging from early research to investigation in a randomized global study in first-line cancer patients. The company’s two novel clinical programs TPST-1120 and TPST-1495, target of PPARα and EP2/EP4, respectively, are advancing through trials designed to study the agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally available inhibitor of TREX1, a target that controls activation of the cGAS/STING pathway. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com.

Investor Contacts:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

---

¹ If approved by the FDA

FAQ

What is the significance of TPST-1495 being presented at ASCO?

The presentation indicates ongoing research interest and potential advancements in oncology.

When will the TPST-1495 abstract be released?

The abstract will be released on May 25, 2023, at 5:00 p.m. ET.

What type of study is being conducted on TPST-1495?

A Phase 1 study evaluating TPST-1495 both as a single agent and in combination with pembrolizumab.

Where will the ASCO Annual Meeting take place?

The ASCO Annual Meeting will be held at the McCormick Place Convention Center in Chicago, IL.

What is the abstract number for the TPST-1495 presentation?

The abstract number is 3107.